Catherine Roberts, NP
Family · Fort Wayne, INNPI 1447210778
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,569 of the $13,304 with a category attached, or 87.0%. Inspire Medical Systems, Inc. accounts for 60.1% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $4,474 and has fallen 68.1% since, to $1,426 in 2025. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 431 payments — averaging $30.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$8K
- AstraZeneca$2K
- GSK$1K
- Sanofi$324
- Boehringer Ingelheim$248
- Takeda Pharmaceuticals U.S.A., Inc.$232
- plus $2K from 16 others
What the payments were for
- Travel & lodging$1,62912%
- Food & beverage$11,56987%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 157 | $7,995 |
| AstraZeneca | 54 | $1,700 |
| GSK | 94 | $1,146 |
| Sanofi | 21 | $324 |
| Boehringer Ingelheim | 10 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $232 |
| Electromed, Inc. | 17 | $229 |
| Mallinckrodt Hospital Products Inc. | 6 | $190 |
| Johnson & Johnson | 6 | $186 |
| Inogen, Inc. | 11 | $183 |
| United Therapeutics Corporation | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 6 | $123 |
| Jazz Pharmaceuticals Inc. | 6 | $103 |
| Philips North America LLC | 6 | $100 |
| Axsome Therapeutics, Inc. | 5 | $99 |
| Harmony Biosciences LLC | 6 | $87 |
| Mylan Specialty L.p. | 5 | $74 |
| Grifols USA, LLC | 4 | $71 |
| AbbVie | 1 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Array Biopharma Inc | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,304 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 574 | $545,361 |
| OfevNintedanib Esylate | 15 | $141,903 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 129 | $115,444 |
| Breo ElliptaFluticasone/Vilanterol | 144 | $94,529 |
| Dupixent PenDupilumab | 17 | $72,180 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 99 | $52,842 |
| SymbicortBudesonide/Formoterol Fumarate | 107 | $43,845 |
| Spiriva RespimatTiotropium Bromide | 49 | $40,830 |
| EliquisApixaban | 40 | $40,277 |
| Spiriva HandihalerTiotropium Bromide | 24 | $26,771 |
| DuleraMometasone/Formoterol | 35 | $23,465 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 135 | $18,083 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $13,546 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 434 | $13,388 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $12,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,146 | $709,427869 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $248 | $209,204105 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,700 | $159,289236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Fort Wayne
- Justin BrownFort Wayne$142K
- Tracy JohnsonFort Wayne$68K
- Grant BlauveltFort Wayne$28K
- Benjamin GiarmoFort Wayne$21K
- Katarzyna SedlaczekFort Wayne$20K
- Brandy DantzerFort Wayne$18K
- Adam ZuberFort Wayne$13K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.